Stock News

Artal Group Sa Has Increased Its Ironwood Pharmaceuticals (IRWD) Holding by $3.00 Million; 683 Capital Management Cut Uniqure Nv (QURE) Position as Market Value Declined

Artal Group Sa increased its stake in Ironwood Pharmaceuticals Inc (IRWD) by 32.42% based on its latest 2017Q3 regulatory filing with the SEC. Artal Group Sa bought 200,000 shares as the company’s stock rose 3.03% with the market. The institutional investor held 816,879 shares of the health care company at the end of 2017Q3, valued at $12.88 million, up from 616,879 at the end of the previous reported quarter. Artal Group Sa who had been investing in Ironwood Pharmaceuticals Inc for a number of months, seems to be bullish on the $2.29B market cap company. The stock increased 5.45% or $0.79 during the last trading session, reaching $15.28. About 935,722 shares traded. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has risen 57.40% since February 15, 2017 and is uptrending. It has outperformed by 40.70% the S&P500.

683 Capital Management Llc decreased its stake in Uniqure Nv (QURE) by 14.28% based on its latest 2017Q3 regulatory filing with the SEC. 683 Capital Management Llc sold 174,936 shares as the company’s stock declined 9.51% while stock markets rallied. The hedge fund held 1.05 million shares of the major pharmaceuticals company at the end of 2017Q3, valued at $10.08 million, down from 1.22 million at the end of the previous reported quarter. 683 Capital Management Llc who had been investing in Uniqure Nv for a number of months, seems to be less bullish one the $741.00 million market cap company. The stock decreased 1.23% or $0.3 during the last trading session, reaching $24.12. About 201,173 shares traded. uniQure N.V. (NASDAQ:QURE) has declined 52.65% since February 15, 2017 and is downtrending. It has underperformed by 69.35% the S&P500.

Among 13 analysts covering uniQure N.V. (NASDAQ:QURE), 10 have Buy rating, 0 Sell and 3 Hold. Therefore 77% are positive. uniQure N.V. had 28 analyst reports since August 7, 2015 according to SRatingsIntel. H.C. Wainwright reinitiated the stock with “Buy” rating in Wednesday, February 24 report. The company was maintained on Wednesday, June 28 by Oppenheimer. The firm has “Hold” rating given on Tuesday, November 22 by Jefferies. The firm has “Buy” rating by Piper Jaffray given on Monday, September 21. The firm earned “Buy” rating on Monday, November 30 by TH Capital. On Monday, August 21 the stock rating was maintained by Oppenheimer with “Buy”. Janney Capital initiated it with “Buy” rating and $40 target in Tuesday, December 1 report. The rating was maintained by Oppenheimer on Monday, September 21 with “Outperform”. On Tuesday, September 22 the stock rating was maintained by Leerink Swann with “Outperform”. As per Tuesday, September 1, the company rating was downgraded by Zacks.

683 Capital Management Llc, which manages about $566.08 million and $951.63 million US Long portfolio, upped its stake in Fogo De Chao Inc by 200,000 shares to 950,000 shares, valued at $11.78M in 2017Q3, according to the filing. It also increased its holding in Select Sector Spdr Tr (Put) (XLU) by 12,300 shares in the quarter, for a total of 400,000 shares, and has risen its stake in Enova Intl Inc.

Analysts await uniQure N.V. (NASDAQ:QURE) to report earnings on March, 21. They expect $-0.72 EPS, down 176.92% or $0.46 from last year’s $-0.26 per share. After $-0.40 actual EPS reported by uniQure N.V. for the previous quarter, Wall Street now forecasts 80.00% negative EPS growth.

Among 15 analysts covering Ironwood Pharmaceuticals (NASDAQ:IRWD), 4 have Buy rating, 2 Sell and 9 Hold. Therefore 27% are positive. Ironwood Pharmaceuticals had 37 analyst reports since August 6, 2015 according to SRatingsIntel. Mizuho downgraded Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) on Wednesday, December 6 to “Neutral” rating. Mizuho maintained the stock with “Buy” rating in Tuesday, May 10 report. The stock of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) earned “Buy” rating by BTIG Research on Friday, December 11. On Friday, February 19 the stock rating was maintained by Wedbush with “Neutral”. The company was maintained on Wednesday, November 1 by Cowen & Co. The stock of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has “Neutral” rating given on Thursday, April 28 by Wedbush. The firm has “Buy” rating by Mizuho given on Monday, October 10. The firm has “Buy” rating by Cowen & Co given on Thursday, July 20. The rating was maintained by Cowen & Co with “Buy” on Monday, August 21. The stock of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) earned “Neutral” rating by Wedbush on Monday, October 24.

Investors sentiment decreased to 1.25 in Q3 2017. Its down 0.06, from 1.31 in 2017Q2. It fall, as 24 investors sold IRWD shares while 32 reduced holdings. 13 funds opened positions while 57 raised stakes. 154.60 million shares or 6.92% more from 144.60 million shares in 2017Q2 were reported. Tiaa Cref Invest Mgmt Ltd Liability Corporation stated it has 350,782 shares or 0% of all its holdings. Tocqueville Asset Ltd Partnership owns 29,612 shares or 0.01% of their US portfolio. Blackrock Inc owns 0.01% invested in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 11.87M shares. Lenox Wealth Advsr invested 0% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). New York-based Amalgamated State Bank has invested 0.01% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Cornerstone Management Ltd Llc has invested 0.01% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). State Board Of Administration Of Florida Retirement has 0% invested in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Penn Capital Management Com holds 1.03% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) or 883,217 shares. Principal Financial Group holds 88,261 shares. The New York-based Alliancebernstein Lp has invested 0% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). California State Teachers Retirement holds 0.01% or 215,473 shares. Raymond James Fincl Svcs Advsrs reported 11,733 shares. Rock Springs Mgmt L P, a Maryland-based fund reported 200,000 shares. Plante Moran Financial Advsrs Ltd Company owns 0% invested in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 79 shares. Macquarie Group Limited owns 111,003 shares.

Since August 18, 2017, it had 0 insider buys, and 3 insider sales for $983,540 activity. Consylman Gina sold 207 shares worth $2,968. Currie Mark G had sold 60,000 shares worth $927,000. On Tuesday, September 5 OLANOFF LAWRENCE S sold $32,300 worth of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) or 2,000 shares.

Artal Group Sa, which manages about $5.81 billion US Long portfolio, decreased its stake in Five Prime Therapeutics Inc (NASDAQ:FPRX) by 100,000 shares to 50,000 shares, valued at $2.05 million in 2017Q3, according to the filing. It also reduced its holding in Calithera Biosciences Inc (NASDAQ:CALA) by 25,000 shares in the quarter, leaving it with 175,000 shares, and cut its stake in Anaptysbio Inc.

Leave a Reply

Your email address will not be published. Required fields are marked *